MediWound Ltd (M8W F) stock market data APIs
€14.7183
0(0%)
as of January 16, 2026
Try our APIs with
free plan!
MediWound Ltd Financial Data Overview
Price chart is built with
Anychart
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Prev. Close
14.7183
Open
14.7183
High
14.7183
Low
14.7183
52 wk Range
12.9-19.4
Market Cap
189 M
Shares Outstanding
12 835 K
Revenue
20 932 K
EPS
-0.12
Beta
0.075
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get MediWound Ltd data using free add-ons & libraries
Get MediWound Ltd Fundamental Data
MediWound Ltd Fundamental data includes:
- Net Revenue: 20 932 K
- EBITDA: -22 664 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-06-30
- EPS/Forecast: -0.07
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
MediWound Ltd News
New
MediWound Announces Commercial Launch of NexoBrid® in Japan
MediWound Ltd. Kaken Pharmaceutical launches NexoBrid under an exclusive marketing and distribution agreement YAVNE, Israel, Aug. 01, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully ...
3 Micro-Cap Stocks to Buy for Multibagger Returns
Micro-cap stocks, by definition, are stocks of companies that trade at a valuation range of $50 to $300 million. It goes without saying that investing in micro-cap stocks is a high-risk game. I would ...
MediWound Announces Positive Results in Its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
MediWound Ltd. MW005shown to be safe and well-tolerated Data provide clinical efficacy proof-of-concept based on clearance of target lesions YAVNE, Israel, July 10, 2023 (GLOBE NEWSWIRE) -- MediWou...
MediWound Receives Positive Scientific Advice from European Medicine Agency (EMA) on EscharEx Phase III Study Design
MediWound Ltd. Affirms the clear path forward for the Company’s global Phase III study of EscharEx in venous leg ulcers YAVNE, Israel, July 03, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDW...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
